Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
MIT
Biotech
After $2.1B Novo deal, Vivtex is just getting started
Despite signing a deal potentially worth $2.1 billion, Vivtex CEO Thomas von Erlach, Ph.D., refuses to rest on his laurels.
Will Maddox
Apr 8, 2026 8:00am
MIT rejects Trump deal tying research money to certain demands
Oct 10, 2025 1:12pm
‘Explainable’ AI finds new antibiotics that stop MRSA in mice
Dec 20, 2023 4:25pm
MIT, MGH make hand-held robot for tapping blood vessels
Mar 21, 2022 11:27am
MIT scientist claims Sabatini 'coerced' sex, led 'offensive' lab
Dec 8, 2021 9:35am
Metis debuts with $86M to bankroll 2022 trial, gene therapy push
Dec 7, 2021 6:00am
